Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Synthetic peptide consisting of 5 amino acids
amilo-5MER · 1 trial · 1 indication
Assess and characterize the number of participants with clinically significant changes in safety assessments, including adverse events, physical examination findings, vital signs, clinical laboratory assessments, and urinalysis.
| Arm | Type | Description |
|---|---|---|
| A- amilo-5MER solution for subcutaneous administration or matching placebo- 10 mg | EXPERIMENTAL | Amilo-5MER solution for subcutaneous administration or matching placebo at a dose of 10 mg |
| B- amilo-5MER solution for subcutaneous administration or matching placebo- 30 mg | EXPERIMENTAL | Amilo-5MER solution for subcutaneous administration or matching placebo at a dose of 30 mg |
| C- amilo-5MER solution for subcutaneous administration or matching placebo- 90 mg | EXPERIMENTAL | Amilo-5MER solution for subcutaneous administration or matching placebo at a dose of 90 mg |
| D- amilo-5MER solution for subcutaneous administration or matching placebo- 180 mg | EXPERIMENTAL | Amilo-5MER solution for subcutaneous administration or matching placebo at a dose of 180 mg |
| E- amilo-5MER solution for subcutaneous administration or matching placebo- 360mg | EXPERIMENTAL | Amilo-5MER solution for subcutaneous administration or matching placebo at a dose of 360 mg |
| Name | Type | Description |
|---|---|---|
| amilo-5MER | DRUG | amilo-5MER is a 5 amino acid synthetic peptide MTADV (Methionine, Threonine, Alanine, Aspartic acid, Valine). |
Inclusion Criteria: 1. Healthy males (all parts) or healthy females (Part 3 only). 2. Aged 18 to 45 years (Parts 1 and 2) or aged 65 to 80 years (Part 3) inclusive at the time of signing informed consent. 3. Body mass index (BMI) of 19.0 to 31.0 kg/m2, with a body weight \<95 kg, as measured at scr...
Amilo-5MER is an investigational small molecule being developed by Eocene Ltd. Ordinary Shares (ticker EOCN) for inflammatory disease. It is in Phase 1 clinical development and has been studied in a first-in-human trial in healthy volunteers. It is not approved for any indication.
Amilo-5MER is being developed for inflammatory disease, an immunology indication. Its only clinical study to date was a first-in-human trial in healthy subjects, so it has not been evaluated for efficacy in patients and is not approved for any use.
Amilo-5MER is developed by Eocene Ltd. Ordinary Shares, which trades under the ticker EOCN. The company is the sponsor of the drug's clinical program in inflammatory disease.
Amilo-5MER is in Phase 1 development. Its single recorded trial, a first-in-human study of single and multiple doses in healthy subjects, has been completed. The drug remains investigational and has not been approved by the FDA or any other regulator.
Amilo-5MER has been studied in one clinical trial, NCT05857215, titled A First-in-Human Study of Single and Multiple Doses of Amilo-5MER in Healthy Subjects. The Phase 1 trial enrolled 55 participants in the United Kingdom, was randomized, double-blind, and controlled, and is now completed.